PubRank

E Solary

Author PubWeight™ 109.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000 4.89
2 A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999 2.98
3 Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997 2.38
4 Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 1994 2.34
5 HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 1999 2.16
6 Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001 1.97
7 Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 2008 1.93
8 Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010 1.75
9 SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013 1.65
10 A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994 1.64
11 Developmental changes in human megakaryopoiesis. J Thromb Haemost 2013 1.63
12 Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999 1.60
13 Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br J Haematol 1995 1.43
14 Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood 1999 1.38
15 Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 1997 1.38
16 Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001 1.38
17 Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000 1.37
18 Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994 1.34
19 Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res 1998 1.25
20 Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia 2013 1.22
21 JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2011 1.21
22 A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 2013 1.21
23 Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993 1.21
24 Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007 1.20
25 The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis. J Virol 2000 1.18
26 Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Cancer Res 1997 1.16
27 Mitochondria in hematopoiesis and hematological diseases. Oncogene 2006 1.11
28 Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 2000 1.11
29 Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. Oncogene 2001 1.09
30 Prophylactic fluconazole and Candida krusei infection. N Engl J Med 1992 1.07
31 The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995 1.07
32 Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem 2011 1.06
33 Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000 1.05
34 Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death Differ 2008 1.05
35 Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J 1996 1.05
36 Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J 1998 1.03
37 An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia 2013 1.03
38 Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ 1998 1.02
39 Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. Oncogene 2001 1.00
40 Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol 2000 0.99
41 Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. Blood 2001 0.98
42 Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. Oncogene 1998 0.98
43 Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol 2001 0.97
44 Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. Oncogene 1999 0.96
45 Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 2010 0.95
46 CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis 2012 0.94
47 Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene 2010 0.94
48 Caspase-2, a novel lipid sensor under the control of sterol regulatory element binding protein 2. Mol Cell Biol 2005 0.94
49 Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene 2006 0.93
50 Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 2001 0.92
51 Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2005 0.90
52 p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999 0.90
53 Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. Cell Death Differ 2005 0.89
54 Caffeine sensitizes human H358 cell line to p53-mediated apoptosis by inducing mitochondrial translocation and conformational change of BAX protein. J Biol Chem 2001 0.89
55 A role of HSPs in apoptosis through "protein triage"? Cell Death Differ 2003 0.88
56 Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade. Cancer Res 2000 0.87
57 Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 2001 0.87
58 Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res 1993 0.87
59 Bone marrow necrosis and human parvovirus associated infection preceding an Ph1+ acute lymphoblastic leukemia. Leuk Lymphoma 1992 0.86
60 The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene 2010 0.86
61 STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun 1999 0.86
62 Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis 1992 0.85
63 Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J 2015 0.85
64 Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia 2012 0.85
65 Identification of a functional DNA binding site for the SREBP-1c transcription factor in the first intron of the human caspase-2 gene. Biochim Biophys Acta 2005 0.84
66 Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death Dis 2013 0.84
67 Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998 0.84
68 Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 1998 0.83
69 Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int J Cancer 1998 0.82
70 Expression of the gadd153 gene in normal and tumor breast tissues by a sensitive RT-PCR method. Int J Mol Med 1999 0.82
71 P27KiP1 overexpression inhibits the growth and doxorubicin sensitivity of HT29 human colon cancer cells in vivo. Anticancer Res 2000 0.82
72 Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes. J Immunol 2000 0.82
73 New insights into the kinetic resistance to anticancer agents. Cytotechnology 1998 0.82
74 Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia 2008 0.81
75 BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998 0.81
76 Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocations. Leukemia 1995 0.81
77 Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death Differ 1999 0.81
78 Evidence for a role of plasticizers in 'eosinophilic' peritonitis in continuous ambulatory peritoneal dialysis. Nephron 1986 0.80
79 Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. Biochim Biophys Acta 2002 0.80
80 Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiogr 2000 0.79
81 A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes. Leukemia 1999 0.79
82 Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: comparison of two monoclonal antibodies and three fluorescent dyes in three cells lines. Anticancer Res 1995 0.79
83 Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 2000 0.79
84 Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth. Cancer Gene Ther 2008 0.79
85 Effects of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. Ann Rheum Dis 2000 0.78
86 PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies. Leuk Lymphoma 1998 0.78
87 Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol 1999 0.78
88 Systemic lupus erythematosus occurring in a patient with multiple myeloma. Arthritis Rheum 1986 0.78
89 High concentrations of intrathecal interleukin-6 in human bacterial and nonbacterial meningitis. J Infect Dis 1992 0.78
90 Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia 2001 0.78
91 Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J 2011 0.77
92 Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia 1994 0.77
93 Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Des 1995 0.77
94 Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia 2002 0.77
95 [Trefoil factor family gene and peptide expression in pterygium]. J Fr Ophtalmol 2003 0.76
96 Infraclinical neuropathies related to immunodeficiency virus infection associated with higher T-helper cell count. J Acquir Immune Defic Syndr 1989 0.76
97 FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. Int J Cancer 1999 0.76
98 Intracellular redistribution of procaspases during TPA-induced differentiation of U937 human leukemic cells. Leukemia 2002 0.75
99 Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. Br J Cancer 1990 0.75
100 [Invasive pulmonary aspergillosis in neutropenic patients. Analysis of a series of 36 cases: contribution of thoracic scanners and itraconazole]. Ann Med Interne (Paris) 1995 0.75
101 Immune mechanisms in HIV-related neuropathies. Lancet 1989 0.75
102 [Early detection of cardiotoxicity of anthracyclines. Value of isotopic method]. Arch Mal Coeur Vaiss 1996 0.75
103 [Treatment of cancer and hematological malignancy in elderly people (Part II)]. Rev Med Interne 2004 0.75
104 [Value of rhodamine 123 in the detection of minor amounts of multidrug resistant cells]. Bull Cancer 1994 0.75
105 Pharmacokinetics of a more reliable Chloraminophene formulation. Nouv Rev Fr Hematol 1995 0.75
106 [Thalidomide with or without dexamethasone for refractory multiple myeloma]. Therapie 2003 0.75
107 Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. Leukemia 1998 0.75
108 Transforming growth factors alpha and beta: a review of their characteristics and potential pharmacological applications. Nouv Rev Fr Hematol 1990 0.75
109 Prognostic relevance of surface markers in adult de novo acute myeloblastic leukemias: a prospective study of the Groupe d'Etude Immunologique des Leucémies (G.E.I.L.). Leuk Lymphoma 1994 0.75
110 Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML. Leukemia 1992 0.75
111 Der(16)t(1;16)(q11;q11) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenic and fluorescence in situ hybridization studies. Br J Haematol 1995 0.75
112 Immunologic analysis of a thousand cases of acute leukemia. French Groupe d'Etude Immunologique des Leucémies (GEIL). Nouv Rev Fr Hematol 1989 0.75
113 Testing the proportional hazards assumption in medical survival studies--application to a population-based study of acute myeloid leukaemia. J Epidemiol Biostat 1999 0.75
114 Molecular pathophysiology of chronic myelogenous leukemia. Hematol Cell Ther 1998 0.75
115 Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplant 1997 0.75
116 BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5. Leuk Lymphoma 2001 0.75
117 Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. Int J Cancer 1995 0.75
118 The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development. Oncogene 2016 0.75
119 [Apoptosis and chemotherapy]. Bull Cancer 1999 0.75
120 A mysterious splenomegaly in a young Turkish patient. Haematologica 2002 0.75
121 [Extramedullary pancreatic localization of myeloma]. Ann Med Interne (Paris) 1989 0.75
122 Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Eur J Haematol 1992 0.75
123 Immunoglobulin phenotype in 164 B cell chronic lymphocytic leukemias: is there a relationship with initial clinical stage and survival? Nouv Rev Fr Hematol 1987 0.75
124 [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. Presse Med 1987 0.75
125 [Treatment of bacterial infections by ofloxacin. 42 cases]. Pathol Biol (Paris) 1987 0.75
126 [Treatment of cancer and hematological malignancy in elderly people: oncogeriatrics as a discipline for the future (Part I): geriatric evaluation and management of solid tumors]. Rev Med Interne 2004 0.75
127 New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in acceleration. Cancer Genet Cytogenet 1992 0.75
128 [Diagnostic value of broncho-alveolar lavage in lung diseases caused by amiodarone]. Presse Med 1989 0.75
129 Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. Bone Marrow Transplant 1998 0.75